With 1.05 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.86 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $70.3812 whereas the lowest price it dropped to was $67.28. The 52-week range on PRCT shows that it touched its highest point at $103.81 and its lowest point at $44.51 during that stretch. It currently has a 1-year price target of $104.11. Beta for the stock currently stands at 1.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PRCT was down-trending over the past week, with a drop of -11.07%, but this was down by -13.79% over a month. Three-month performance surged to 2.11% while six-month performance rose 0.33%. The stock gained 49.25% in the past year, while it has lost -13.51% so far this year. A look at the trailing 12-month EPS for PRCT yields -1.95 with Next year EPS estimates of -1.30. For the next quarter, that number is -0.34. This implies an EPS growth rate of 22.27% for this year and 25.49% for next year.
Float and Shares Shorts:
At present, 52.15 million PRCT shares are outstanding with a float of 51.55 million shares on hand for trading. On 2024-12-31, short shares totaled 6.89 million, which was 1273.0 higher than short shares on 1732838400. In addition to Dr. Reza Zadno Ph.D. as the firm’s President, CEO & Director, Mr. Kevin Waters serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.87921995 of PRCT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PRCT reported revenue of $58370000.0 and operating income of -$22427000.0. The EBITDA in the recently reported quarter was -$18506000.0 and diluted EPS was -$0.4.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PRCT since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PRCT analysts setting a high price target of 112.0 and a low target of 95.0, the average target price over the next 12 months is 102.75. Based on these targets, PRCT could surge 60.83% to reach the target high and rise by 36.42% to reach the target low. Reaching the average price target will result in a growth of 47.54% from current levels.
Analysts have provided yearly estimates in a range of -$1.69142 being high and -$1.83072 being low. For PRCT, this leads to a yearly average estimate of -$1.74117.
